-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pepinemab in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pepinemab in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pepinemab in Pancreatic Ductal Adenocarcinoma Drug Details: Pepinemab (VX-15) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Budigalimab in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Budigalimab in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Budigalimab in Triple-Negative Breast Cancer (TNBC) Drug Details: Budigalimab (ABBV-181)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pepinemab in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pepinemab in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pepinemab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 4D-110 in Choroideremia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 4D-110 in Choroideremia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.4D-110 in ChoroideremiaDrug Details:4D-110 is under development for the treatment of choroideremia. The therapy...
-
Company Insights
Innovation and Patenting activity of 4D Molecular Therapeutics Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of 4D Molecular Therapeutics Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dalzanemdor in Huntington Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dalzanemdor in Huntington Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dalzanemdor in Huntington Disease Drug Details: Dalzanemdor (SAGE-718) is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Pirtobrutinib in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pirtobrutinib in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pirtobrutinib in Follicular Lymphoma Drug Details: Pirtobrutinib (Jaypirca) is an anti-neoplastic agent. It...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Vidutolimod in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vidutolimod in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vidutolimod in Metastatic Colorectal Cancer Drug Details: CMP-001 (CYT-003) is...